Journal of Orthopedic Oncology
Open Access

Bone cancer; Bone Microarchitecture; Chondrosarcoma; Bone Turnover; Osteosarcoma

Introduction

Symptoms of bone cancer include pain in the bone that gets worse with activity or at night, swelling or a lump in the affected area, weakness or fatigue, and weight loss [1]. The diagnosis of bone cancer involves a physical examination, imaging tests such as X-rays and CT scans, and a biopsy to confirm the presence of cancerous cells. Treatment for bone cancer varies depending on the type [2], stage, and location of the cancer. Surgery is often the first choice of treatment for primary bone cancer, with the goal being to remove the entire tumor and any surrounding tissue that may contain cancer cells [3]. Chemotherapy and radiation therapy may also be used before or after surgery to destroy cancerous cells. For secondary bone cancer, the treatment is focused on the primary cancer that has spread to the bones. Chemotherapy, radiation therapy, and hormone therapy may be used to treat the primary cancer and reduce the spread of cancer to the bones [4].

Method

Prognosis for bone cancer varies depending on the type and stage of the cancer and the treatment received. For primary bone cancer, the five-year survival rate is around 70%. For secondary bone cancer, the survival rate varies depending on the stage of the primary cancer and the location of the bone metastasis. bone cancer is a rare but serious type of cancer affecting the bones of the body. The symptoms of bone cancer can be similar to those of other bone conditions, and an accurate diagnosis involves a physical examination, imaging tests, and a biopsy. Treatment for bone cancer typically involves surgery [5], chemotherapy, and radiation therapy. Prognosis varies depending on the type and stage of the cancer and the treatment received. It is essential to seek medical attention promptly if you experience any symptoms of bone cancer to receive a timely diagnosis and appropriate treatment.

In this mini-review, we will discuss the most common types of bone cancer.

Osteosarcoma

Osteosarcoma is the most common type of bone cancer and typically occurs in children and young adults. It starts in the bone cells that produce new bone tissue and often develops in the long bones of the arms and legs. The symptoms of osteosarcoma include bone pain, swelling, and tenderness in the affected area. Treatment usually involves surgery to remove the tumor and affected bone, followed by chemotherapy to kill any remaining cancer cells [6].

Chondrosarcoma

Chondrosarcoma is the second most common type of bone cancer and typically affects adults over the age of 40. It starts in the cartilage cells that produce new cartilage tissue and often develops in the pelvis, thigh bone, or upper arm bone. The symptoms of chondrosarcoma include bone pain, swelling, and stiffness in the affected area. Treatment usually involves surgery to remove the tumor, but chemotherapy and radiation therapy are generally not effective [7].

Ewing’s sarcoma

Ewing’s sarcoma is a rare type of bone cancer that typically affects children and young adults. It starts in the bone marrow and often develops in the pelvis, thigh bone, or upper arm bone. The symptoms of Ewing’s sarcoma include bone pain, swelling, and tenderness in the affected area, as well as fever and fatigue. Treatment usually involves a combination of surgery, chemotherapy, and radiation therapy.

Giant cell tumor of bone

Giant cell tumor of bone is a rare type of bone cancer that typically affects young adults. It starts in the bone cells that break down old bone tissue and often develops in the knee or the bones of the hands and feet. The symptoms of giant cell tumor of bone include bone pain, swelling, and tenderness in the affected area. Treatment usually involves surgery to remove the tumor, but radiation therapy may also be used in some cases [8].

Chordoma

Chordoma is a rare type of bone cancer that typically affects adults over the age of 30. It starts in the cells that support the spinal cord and often develops in the bones of the skull or spine. The symptoms of chordoma include back pain, headaches, and numbness or weakness in the arms or legs. Treatment usually involves surgery to remove the tumor, but radiation therapy may also be used in some cases.

Malignant fibrous histiocytoma of bone

Malignant fibrous histiocytoma of bone is a rare type of bone cancer that typically affects adults over the age of 50. It starts in the cells that produce connective tissue and often develops in the thigh bone or upper arm bone. The symptoms of malignant fibrous histiocytoma of bone include bone pain, swelling, and tenderness in the affected area. Treatment usually involves surgery to remove the tumor, but chemotherapy and radiation therapy may also be used. Bone cancer is a rare type of cancer that can affect people of all ages. There are several different types of bone cancer, each with its own characteristics, symptoms, and treatment options. The most common types of bone cancer include osteosarcoma, chondrosarcoma, and Ewing’s sarcoma, giant cell tumor of bone, chordoma, and malignant fibrous histiocytoma of bone [9]. Treatment usually involves surgery to remove the tumor, but chemotherapy and radiation therapy may also be used in some.

Results

The GDNF-GFRa1 signaling pathway is involved in the activation and sensitization of non-pep- tidergic bone afferent neurons in inflammatory bone pain, which typically occurs in bone cancer . After peripheral nerve injury, DRG neurons showed an increase in GFRa1 expression at the mRNA and protein levels . The activation of GDNFGFRa1- ERK-Runx1 signaling in the DRG neurons of bone cancer pain rats was strongly supported by our findings of an elevated level of GDNF, an increased abundance of GFRa1, and phosphorylated ERK and Runx1 in the ipsilateral L4/5 DRGs of tumor-bearing rats. In concurrence with these discoveries, we tracked down that thumping down GFRa1 in DRG neurons by intrathecal GFRa1-AS ODN inhibits neuronal hyperexcitability and pain hypersensitivity in bone metastasis model rats by suppressing the activation of ERK-Runx1 signaling and the transcription of the P2X3R gene in DRG neurons. In a similar vein, an intrathecal ERK inhibitor or an intrathecal interfering peptide targeting the serine 249 Runx1 site (TAT-Ser) can disrupt the activation of ERK-Runx1 signaling in DRG neurons, resulting in a reduction in neuronal hyperexcitabil-ity and pain hypersensitivity in bone cancer pain model rats [10].

Discussion

Taken together, these information give strong proof exhibiting that the actuation of GDNF-GFRa1-Ret-ERK flagging is associated with the up regulation of Runx1-interceded P2X3R quality record in DRG neurons and in the pathogenesis of torment touchiness in bone malignant growth rodents. Of note, the wellspring of expanded GDNF fixation distinguished in DRG tissues was not analyzed. DRG tactile neurons are recommended as one of the starting points of collected GDNF in the cut across sciatic nerve, where a sub gathering of little to medium-sized DRG neurons combined GDNF-containing thick cored vesicles in the neuronal somata and anterograde transports the vesicles to the nerve terminals. In addition, chronic sciatic nerve injury increases GDNF mRNA and protein expression in Schwann cells and DRG satellite cells , these glia-derived GDNF are taken up by DRG neurons and transported anteriorly along the axons for release from terminals. Pre-osteoclasts can also secrete GDNF to control the migration and osteogenesis of bone marrow mesenchymal stem cells (BMSCs) and facilitate osteoclast-osteoblast crosstalk. BMSC can likewise repress neuroinflammation by emitting GDNF to direct microglial polarization, consequently mitigating differentiation torment in rodents.

Conclusion

GDNF expression in activated astrocytes, microglia, and infiltrating macrophages has been reported to be induced by neuroinflammation, which may occur during bone cancer pain. Under pathological conditions, some reports also describe the upregulation of Ret and GFRa1 in glial cells, proposing that potential non-neuronal instrument as play also. Even though intrathecal exogenous GDNF produced mechanical hypersensitivity and thermal hyperalgesia in naive rats and GFRa1-AS abrogated the augmented pain hypersensitivity including both mechanical hypersensitivity and thermal hyperalgesia in bone cancer rats, we are unable to provide a clear explanation for why the relief from thermal hyperalgesia is not evident after interfering with the ERK-Runx1 signaling. The error saw between the inversion of warm hyperalgesia with GDNF/GFRa1-AS may be made sense of by the enactment of downstream pathways other than ERK flagging. Although it was only demonstrated in this study that GDNF upregulation of P2X3R is mediated by ERK, other signaling cascades may be involved in bone cancer pain. Also, in Runx1 knockout mice the warm edges are expanded, and that several models of acute and chronic pain show decreased thermal and mechanical hyperalgesia when P2X3R is blocked. Therefore, the fact that interfering with the ERK-Runx1 signaling did not affect thermal hyperalgesia could be attributed to other transcriptional targets other than P2X3R. In the coming research, it will be necessary to investigate the potential mechanisms underlying thermal hyperalgesia for pain caused by bone cancer.

1. Coughlin MJ, Shurnas PS (2003) Hallux rigidus. Grading and long-term results of operative treatment. J Bone Joint Surg Am 85: 2072-2088.

Indexed at, Google Scholar

2. Chraim M, Bock P, Alrabai HM, Trnka HJ (2016) Long-term outcome of first metatarsophalangeal joint fusion in the treatment of severe hallux rigidus. Int Orthop 40: 2401-2408.

Indexed at, Google Scholar, Crossref

3. Kumar S, Pradhan R, Rosenfeld PF (2010) First metatarsophalangeal arthrodesis using a dorsal plate and a compression screw. Foot Ankle Int 31: 797-801.

Indexed at, Google Scholar, Crossref

4. Morgan S, Ng A, Clough T (2012) The long-term outcome of silastic implant arthroplasty of the first metatarsophalangeal joint: a retrospective analysis of one hundred and eight feet. Int Orthop36: 1865-1869.

Indexed at, Google Scholar, Crossref

5. Shereff MJ, Jahss MH (1980) Complications of silastic implants arthroplasty in the hallux. Foot Ankle 1: 95-101.

Indexed at, Google Scholar, Crossref

6. Cracchiolo A, Weltmer JB, Lian G, Dalseth T, Dorey F (1992) Arthroplasty of the first metatarsophalangeal joint with a double-stem silicone implant: results in patients who have degenerative joint disease failure of previous operations, or rheumatoid arthritis. J Bone Joint Surg 74: 552-563.

Indexed at, Google Scholar

7. McNearney T, Haque A, Wen J, Lisse J (1996) Inguinal lymph node foreign body granulomas after placement of a silicone rubber (Silflex) implant of the first metatarsophalangeal joint. J Rheumatol 23: 1449-1452.

Indexed at, Google Scholar

8. Sammarco GJ, Tabatowski K (1992) Silicone lymphadenopathy associated with failed prosthesis of the hallux: a case report and literature review. Foot Ankle 13: 273-276.

Indexed at, Google Scholar, Crossref

9. Eble SK, Hansen OB, Chrea B (2020) Clinical Outcomes of the Polyvinyl Alcohol (PVA) Hydrogel Implant for Hallux Rigidus. Foot Ankle Int 41: 1056-1064.

Indexed at, Google Scholar, Crossref

10. Geraghty S, Kuang J, Yoo D, LeRoux-Williams M, Vangsness CT Jr, et al. (2015) A novel, cryopreserved, viable osteochondral allograft designed to augment marrow stimulation for articular cartilage repair. Journal of Orthopaedic Surgery and Research 20: 66-75.

Indexed at, Google Scholar, Crossref